IN BRIEF (Page 16)

Record leap

Karo Bio AB, the Swedish drugmaker developing an experimental cholesterol drug, had a record increase in Stockholm trading after a study showed the treatment helped patients taking medicines such as Pfizer Inc's Lipitor.

Karo Bio climbed as much as 3.25 kronor, or 60 percent, the steepest rise since shares started trading in April 1998, and gained 39 percent to 7.45 kronor at 9:41 am. That gives the Huddinge, Sweden-based company a market value of 865 million kronor ($142 million).